This mechanism of action of binding competitively to the CCR5 receptor differentiates leronlimab from all other CCR5 antagonists.”

Investors Hangout: https://investorshangout.com/post/view?id=667...z8THKxsB8o

I sometimes cannot believe the market and so called big pharma is so slow witted about the potency and range of LL as a therapeutic. Patience Bunky.